RXRX earnings: real EPS beat/miss history, analyst consensus Hold, P/E -2.48. Updated 2026-07-23.
Recursion Pharmaceuticals (RXRX) Research Hub
Recursion Pharmaceuticals (RXRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.2 USD (-0.62%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.48, market cap 1.34B. This hub links to the full technical, earnings and options research available for RXRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.2 USD (-0.62%) |
| 52-week range | 2.84 USD – 4.09 USD |
| Trend regime | Range |
| 14-day RSI | 49.4 (Neutral) |
| Trailing P/E | -2.48 |
| Market cap | 1.34B |
| Dividend yield | 0.00% |
Available research for RXRX
Covered Call on RXRX: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RXRX: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RXRX: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
RXRX technical analysis: range, last 3.2 USD, RSI 49.4, 52w range 2.84 USD–4.09 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RXRX in?
Recursion Pharmaceuticals (RXRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RXRX in an uptrend or downtrend?
As of 2026-09-11, RXRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RXRX's trailing P/E ratio?
RXRX's trailing P/E is -2.48, with a market cap of 1.34B. See the earnings research page for full valuation detail.